Teva Pharmaceutical Industries (NYSE:TEVA) Announces Quarterly Earnings Results

Teva Pharmaceutical Industries (NYSE:TEVA) issued its quarterly earnings results on Wednesday. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31, FiscalAI reports. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the prior year, the business posted $0.71 earnings per share. The business’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries updated its FY 2026 guidance to 2.570-2.770 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Management reported year-over-year growth in revenue and profitability, noting EBITDA up ~12%, EPS up ~19% and free cash flow improvement, which management says supports their pivot to an innovative biopharma model.
• The commercial portfolio is driving momentum—AUSTEDO, UZEDY and AJOVY delivered strong sales with AUSTEDO guidance of $2.4B–$2.55B and rapid uptake of AUSTEDO XR and UZEDY long‑acting injectable volumes cited as growth drivers.
• Several near‑term R&D catalysts are expected in 2026, including duvakitug maintenance data (H1), olanzapine LAI EU submission/anticipated approval, Anti‑IL‑15 vitiligo and celiac readouts, and completion of the DARI phase‑3 asthma study.
• Financial restructuring and efficiency progress — net debt reduced to about $13B (~2.5x EBITDA), $70M of transformation savings realized toward a $700M target by 2027, and management expects improving margins and deleveraging toward investment‑grade metrics.
• Management flagged near‑term headwinds and one‑offs: an expected ~ $1.1B generic Revlimid revenue decline in 2026, Q1 softness from Revlimid and AUSTEDO destocking/gross‑to‑net effects, and a Q4 impairment charge (~$773M) that weighed on GAAP results.

Teva Pharmaceutical Industries Trading Down 0.5%

Shares of Teva Pharmaceutical Industries stock opened at $33.04 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The firm has a market cap of $37.90 billion, a price-to-earnings ratio of 27.54, a PEG ratio of 1.89 and a beta of 0.66. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $33.44. The business has a 50-day moving average price of $30.29 and a 200-day moving average price of $23.03.

Analysts Set New Price Targets

Several research firms recently issued reports on TEVA. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Truist Financial lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Wall Street Zen cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Sunday, January 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $35.67.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. This trade represents a 70.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the sale, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This trade represents a 80.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 622,060 shares of company stock valued at $17,076,965 in the last ninety days. Corporate insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 15.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after buying an additional 540 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Teva Pharmaceutical Industries by 0.5% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock worth $1,981,000 after acquiring an additional 615 shares during the last quarter. Pathstone Holdings LLC raised its position in Teva Pharmaceutical Industries by 1.2% during the third quarter. Pathstone Holdings LLC now owns 67,884 shares of the company’s stock valued at $1,371,000 after purchasing an additional 792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 15.7% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,310 shares of the company’s stock worth $127,000 after purchasing an additional 856 shares during the period. Finally, Cerity Partners LLC increased its position in shares of Teva Pharmaceutical Industries by 2.9% during the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after purchasing an additional 1,291 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.